- Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma modelHolly A F Stessman
Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA
Mol Cancer Ther 12:1140-50. 2013..This study represents an important next step in translating pharmacogenomic profiling and may be useful for understanding personalized pharmacotherapy for patients with multiple myeloma...
- Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survivalBrian Van Ness
Cancer Center, University of Minnesota, Minneapolis, MN, USA
BMC Med 6:26. 2008..To explore SNP associations with PFS we compared SNP profiles of short term (less than 1 year, n = 70) versus long term progression-free survivors (greater than 3 years, n = 73) in two phase III clinical trials...
- High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactionsGang Fang
Department of Computer Science, University of Minnesota, Minneapolis, Minnesota, United States of America
PLoS ONE 7:e33531. 2012..Thus, our approach is an alternative methodology for exploring the genetics of rare diseases for which the current focus is on individually rare variations...